All News
Filter News
Found 3,892 articles
-
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
11/13/2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the third quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.
-
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
11/10/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.
-
Immunome Reports Third Quarter 2023 Financial Results
11/9/2023
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
-
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
11/9/2023
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.
-
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
11/9/2023
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the third quarter of 2023 and business highlights.
-
This week, in (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more.
-
With headwinds in the wider biotech sphere, the third quarter showed continuing vulnerabilities in the COVID space while the weight-loss drugs drove blockbuster sales.
-
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
11/8/2023
Immunome, Inc. today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.
-
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
11/8/2023
Lantern Pharma Inc. announced operational highlights and financial results for the third quarter ended September 30, 2023.
-
Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology
11/8/2023
Araris Biotech AG announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.
-
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
11/7/2023
Mersana Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.
-
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/7/2023
ADC Therapeutics SA reported financial results for the third quarter 2023 and provided business updates.
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/7/2023
Corbus Pharmaceuticals Holdings, Inc. today provided a corporate update and reported financial results for the third quarter of 2023.
-
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
11/7/2023
ADC Therapeutics SA announced that on October 10, 2023, it received a notice from the New York Stock Exchange that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
-
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial
11/7/2023
BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.
-
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
11/7/2023
BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.
-
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
11/7/2023
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases
-
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 2023 financial results and provided a business update.
-
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
11/7/2023
Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced initiatives to extend its cash runway, reported financial results for the quarter ended September 30, 2023, and provided a corporate update.